VRE’dan korunma ve kontrol yöntemleri
Enterokoklarin hastadan hastaya direkt transferinin, veya indirekt olarak kontamine eller, kontamine yüzeyler ya da tibbi cihazlar yoluyla transferinin mümkün oldugu da gösterilmistir. VRE yayiliminin önlenmesi amaciyla rehberler gelistirilmistir. Hospital Infection Control Practices Advisory Committee (HICPAC) önerileri günümüzde en fazla kabul görmektedir (51). Uygun vankomisin kullanimi, hastane personelinin egitimi, mikrobiyoloji laboratuarinin etkin kullanimi, kontrol önlemlerinin uygulanmasi olarak özetlenebilir.
Kaynaklar
1.English BK, Shenep JL. Enterococcal and Viridans Streptococcal infections. In:Feigin RD, Cherry JD (eds). Textbook of Pediatric Infectious Diseases. 5th edition. Philedelphia: WB Saunders Company, 2004, 1175-92.2.Gray JW, George R H. Experience of vancomycin-resistant enterococci in a childrens hospital. J Hosp Infect 2000; 45: 11-8. 3.Boyce JM, Opal SM, Chow JW, et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol. 1994 May;32(5):1148-53.4.Livornese LL Jr, Dias S, Samel C, et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 1992; 117:112-16.5.Bhavnani SM, Drake JA, Forrest A, et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and –susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000; 36: 145-58. 6.Murray BE. Editorial response: What can we do about vancomycin-resistant enterococci. Clin Infect Dis 1995; 20; 1134-6.7.Murray BE. Diversity among multidrug-resistant enterococci. Emerg Infect Dis 1998; 4; 37-47.8.Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342; 710-21.9.Bratcher DF. Vancomycin-resistant enterococci in the pediatric patient. Pediatr Infect Dis 2001; 20: 621-2. 10.Maniatis AN, Pournaras S, Kanellopoulou M, Kontos F, Dimitroulia E, Papafrangas E, Tsakris A. Dissemination of clonally unrelated erythromycin and glycopeptide-resistant Enterococcus faecium isolates in a tertiary Greek hospital. J Clin Microbiol 2001; 39: 4571.11.Saka V, Tsiodras T, Galani L, et al. Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci. Clin Microbiol Infect 2007; 10.1111/j.1469-0691.2007.01840.x12.Ashkenazi S, Even-Tov S, Sarma Z, et al. Uropathogens of various childhood populations and their antbiotic suceptibility. Pediatr Infect Dis 1991; 10: 742-6. 13.Davies H, Jones E, Sheng R, et al. Nosocomia urinary tract infections at a pediatric hospital. Pediatr Infect Dis 1992; 11: 349-54. 14.Murray BE. The life and times of the enterococcus. Clin Microbiol Rev 1990; 146: 1549-51. 15.Honkinen O, Lehtonen OP, Ruuskanen O, et al. Cohort study of bacterial species causing urinary tract infection and urinary tract abnormalities in children. BMJ 1999; 318: 770-1.16.Bitsori M, Maraki S, Raissaki M, et al. Community aquired enterococcal urinary tract infections. Pediatr Nephrol 2005; 20: 1583-6. 17.Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Pediatrics 1999; 103: e39. 18.Ferrieri P, Gewitz MH, Gerber MA, et al. Unique features of infective endocarditis in childhood. Pediatrics 2002; 109: 931-43.19.Johnson DH, Rosenthal A, Nadas AS. Bacterial endocarditis in children under 2 years of age. Am J Dis Child 1995; 129: 183-6.20.Sandoe JA, Witherden IR, Au-Yeung HGC, Kite P, Kerr KG, Wilcox MH. Enterococcal intravascular catheter-related bloodstream infection: management and outcome of 61 consecutive cases. J Antimicrob Chemot 2002; 50: 577-82.21.Das I, Gray J. Enterococcal bacteremia in children: A review of seventy-five episodes in a pediatric hospital. Infect Dis J 1998: 17: 1154-8.22.Boulanger JM, Ford-Jones EL, Matlow AG. Enterococcal bacteremia in pediatric institutin: A four year review. Rev Infect Dis 1991; 13: 847.23.Butler KM. Enterococcal Infection in Children. Semin Pediatr Infect Dis 2006; 17: 128-39.24.Barie PS, Christou NV, Dellinger EP, et al. Pathogenicity of the enterococcus in surgical infections. Ann Surg 1990; 212: 155-9.25.Brook I. Intra-abdominal, retroperitoneal, and visceral abscesses in children. Eur J Pediatr Surg 2004; 14: 265-73.26.Harbarth S, Uckay I. Are there patients with peritonitis who require empiric therapy for enterococcus? Eur J Clin Microbiol Infect Dis 2004; 23: 73-7.27.Lucas da Silva PS, Neto HM, Sejas LM. Successful Treatment of Vancomycin-Resistant Enterococcus Ventriculitis in a Child. BJID 2007; 11: 297-9.28.Nagai K, Yuge K, Ono E, et al. Enterococcus faecium meningitis in a child. Pediatr Infect Dis 1994; 13: 1016-7.29.Pintado V, Cabellos C, Moreno S, et al. Enterococcal meningitis: a clinical study of 39 cases and review of the literature. Medicine 2003; 82: 346-64.30.McNeeley DF, Saint-Louis F, Noel GJ. Neonatal enterococcal bacteremia: An increasingly frequent event with potentially untreatable pathogens. Pediatr Infect Dis 1996; 15: 800-5.31. Sohn AH, Garret DO, Sinkowitz-Cochran RL, et al. Prevalence of nosocomial infections in neonatal intensive care unit patients: Results from the first national point-prevalance survey. J Pediatr 2001; 139: 821-7.32.Gold H. Vacomycin-resistant enterococci: Mechanisms and clinical observations. Clin Infect Dis 2000; 33: 210-9.33.Lambiase A, Del Pezo M, Piazza O, Petagna C, De Luca C, Rossano F. Typing of Vacomycin-resistant enterococcus faecium strains in a cohort of patients in an Italian intensive care unit. Infection 2007; DOI 10.1007/s15010-007-6288-4.34.Vural T, Sekercioglu AO, Ögünç D, ve ark. Vankomisine dirençli E. faecium susu. Ankem Derg, 1999; 13: 1 – 5.35.Basustaoglu A., Özyurt M., ve ark. Kan kültürlerinden izole edilen glikopeptid dirençli E. faecium. Flora 2000; 5: 142-7.36.Çetinkaya Y., Falk P., Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000; 13: 686 – 707.37.Rice LB. Emergence of vancomycin-resistant enterococci. Emerg Infect Dis 2001; 7: 183 – 7.38.Pest V, Tallon CS, Sanchez A, et al. Epidemiological, microbiological, clinical and prognostic factors of bacteremia caused by high-level vancomycin-resistant Enterococcus species. Eur J Clin Microb Infect Dis 2000; 19: 742 – 9.39.Tan TQ. Update on the use of linezolid. Pediatr Infect Dis J 2004; 23:955-6.40.Bozdogan B, Esel D, Whitener C, Frederick AB, Appelbaum PC. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2003; 52:864-8.41.Bozdogan B,Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 2004; 23:113-9.42.Bostic GD, Peri MB, Thal LA, Zervos MJ. Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistant enterococci. Diagn Microbiol Infect Dis 1998; 30:109-12.43.Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J 2003; 22: S153-S157. 44.Narang M, Gomber S, Linezolid. Indian Pediatrics 2004; 41: 1129-32.45.Jones RN, Ballow CH, Douglas JB, the ZAPS study group medical centers. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: report of the zyvox antimicrobial potency study (ZAPS) in the United States. Diagn Microbiol Infect Dis 2001; 40:59-66.46.Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003; 36.159-68.47.Saiman L, Goldfareb J, Kaplan SA, Wible K, Edege-Padbury B, Naberhuis-Stehouwer S, Bruss JB.. Safety and tolerability of linezolid in children. Pediatr Infect Dis J 2003; 22:S193-S200. 48.Gerson SL, Kaplan SL, Bruss JB, et al. Haematological effects of linezolid: summary of clinical experince. Antimicrob Agents Chemother 2002; 46:2723-6.49.Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial susceptibility of garm-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004). Clin Microbiol Infect 2006; 12 (9): 844-52.50.Macsini EM, Bonten MJ. Vacomycin-resistant enterococci: consequences for therapy and infection control. Clin Mircobiol Infect 2005;Suppl: 43-56.51.Centers for Disease Control and Prevention: Management of multidrug-resistant organisms in healthcare settings. Siegel JD, Rhinehart E, Jackson M, Chiarello L, The Healthcare infection Control Practices Advisory Committee. 2006; 1-74.
